Biogen Hemo Therapy Travels 'A-LONG' Pathway to Success
Last fall, when Biogen Idec Inc. and partner Swedish Orphan Biovitrum made public the Phase III from A-LONG, a trial testing their long-lasting recombinant factor VIII candidate – since branded Eloctate – in hemophilia A, most analysts were pleased but cautious.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter